Fountain Therapeutics develops first-in-class therapies targeting age-related conditions, utilizing biomolecular research and regenerative medicine techniques to enhance subcutaneous fat and preserve lean muscle mass. Their lead programs specifically address skin atrophy and sarcopenia, providing non-invasive alternatives to traditional treatments and mitigating the effects of aging on healthspan.
Funding
$26M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Age-related conditions such as skin atrophy and sarcopenia (lean muscle loss) significantly impact healthspan and quality of life. Current treatments for these conditions can be invasive, require frequent clinic visits, or may have undesirable side effects, particularly in the context of weight loss induced by GLP agonists.
Solution
Fountain Therapeutics develops first-in-class therapies targeting the underlying biological mechanisms of aging to combat skin and lean tissue atrophy. Their lead program for skin atrophy utilizes a topically applied combination of FTX002600 and FTX003059 to directly increase subcutaneous fat, reversing age- and weight loss-associated skin thinning. For sarcopenia, Fountain has identified FTX008762, a small molecule modulator that preserves lean tissue and muscle mass, particularly in individuals experiencing atrophy due to aging or GLP agonist treatments. These non-invasive therapies aim to provide safer, more accessible alternatives to traditional treatments, improving patient outcomes and overall well-being.
Target Audience
The primary target audience includes individuals experiencing age-related skin atrophy and sarcopenia, as well as those undergoing weight loss treatments using GLP agonists who are at risk of lean muscle loss.
Features
- Topical application of FTX002600 and FTX003059 to increase subcutaneous fat and reverse skin atrophy
- FTX008762, a small molecule modulator, to preserve lean tissue and muscle mass
- Programs address skin atrophy associated with aging and weight loss
- Programs address sarcopenia associated with aging and GLP agonist treatments
- Aims to provide non-invasive alternatives to traditional treatments
- Utilizes in vitro and in vivo screening platforms for identifying therapeutic targets